Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Group 1 - Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing innovative therapies with potential clinical benefits for targeted patient populations [2] - The company plans to host a conference call and webcast on March 27, 2025, at 4:30 PM ET to discuss recent business progress and financial results for Q4 ended December 31, 2024 [1][4] - The lead investigational program, NDV-01, is being evaluated in a Phase 2 study for High-Grade Non-Muscle Invasive Bladder Cancer [3] Group 2 - Preparations are underway to advance sepranolone, a Phase 2b-ready investigational program for compulsion-related disorders, including Tourette's Syndrome, into further studies [3]